ISARIC has been committed to provide a wide breadth of COVID-19 clinical research resources since the beginning of the outbreak. These resources are fully adaptable and completely free to use
The tools below aim to cover a range of tiers, suitable for different needs:
- Data collection only
- Contributing clinical data
- Research protocols
- Guidance to start your study
- ISARIC’s affiliated studies
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Visit this section to find ISARIC’s articles, studies and more.
Time to reconsider the role of ribavirin in Lassa fever
Ribavirin is the only available Lassa fever–specific treatment and has been used routinely for over 25 years. However, ribavirin is not licensed for Lassa fever, its mechanism of action is unclear, it is expensive and hard to source, and it has well-known toxicities.
Women under 50 had worse long-term outcomes after hospitalisation with COVID-19
Women under 50 and people who experienced severe disease had worse long-term outcomes following hospitalisation with COVID-19.
Key inflammatory markers identified in COVID-19
ISARIC, supported by the UK Coronavirus Immunology Consortium (UK-CIC), has identified new biomarkers of inflammation that both indicate the severity of COVID-19 and distinguish it from severe influenza.